Vaxcyte, Inc.

Сильный индекс, значительно упал. Быки в растерянности.

Strong index, significantly down. The bulls are confused.

Сильный индекс, незначительно упал. Рынок не поддерживает быков.

Strong index, slightly down. The market does not support the bulls.

Средний индекс, незначительно вырос. Отток средств из лонгов на высоком уровне.

Medium index, slightly up. Outflow of funds from longs at a high level.

Key Points
Andrew Guggenhime surrendered 2,705 shares at $61.18 per share on August 31 and September 2, representing a transaction value of $165,492.
The transaction size represents 2% of the total equity stake held before the filing.
All 2,705 shares were disposed of directly, while 61,850 shares remain held indirectly through an LLC.
President and CFO Andrew Guggenhime reported the disposition of 2,705 shares of Vaxcyte, Inc. (NASDAQ:PCVX), according to a recent SEC Form 4 filing.
Transaction summary
Transaction value
~$165,492
Shares sold (directly held)
2,705
Post-transaction shares (total)
164,321
Post-transaction shares (directly held)
102,471
Post-transaction shares (indirectly held)
61,850
Post-transaction value
$10.12 million
Transaction value based on SEC Form 4 weighted average sale price ($61.18); post-transaction value based on the September 2 market close ($61.58).
Key questions
What was the specific nature of this disposition?
The transaction involved 2,705 shares that were surrendered directly to the company to satisfy tax withholding obligations. This occurred automatically upon the vesting of restricted stock units and was not a discretionary open-market sale.
How is the insider's total equity structured?
Guggenhime retains about 164,000 shares of Vaxcyte, consisting of 102,000 shares held directly and 61,850 shares held indirectly via ALG 2025 Grat Holdings LLC. The total position was valued at $10.12 million based on the September 2 market close.
What is the recent performance context for the security?
Vaxcyte shares have seen a 95% return over the one-year period ending September 2. This performance context coincides with the ongoing clinical development of the company's experimental vaccine candidates, including VAX-24.
Company Overview
Share Price (as of market close 2026-09-01)
$60.81
Market Capitalization
$9.0 billion
Net Income (TTM)
-$1.1 billion
Company Snapshot
Vaxcyte is a clinical-stage biotechnology company focused on developing innovative protein-based vaccines to prevent and manage bacterial infectious diseases, with its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine currently in clinical trials.
The company operates a development-stage business model centered on advancing proprietary vaccine candidates through clinical trials with the objective of eventual commercialization and licensing partnerships with established pharmaceutical entities.
Vaxcyte's primary target markets include healthcare systems, public health agencies, and pharmaceutical partners seeking next-generation vaccines to address unmet medical needs in infectious disease prevention, particularly in immunocompromised and elderly populations.
Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees, focused on developing next-generation protein-based vaccines addressing significant gaps in infectious disease prevention. The company's strategic approach leverages advanced conjugate vaccine technology to create multi-valent formulations with enhanced immunogenicity and broader pathogen coverage compared to existing therapeutic options. With a market capitalization of $9.0 billion and a one-year share price appreciation of 95.12%, Vaxcyte represents investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector.
What this transaction means for investors
Guggenhime handed 2,705 shares back to Vaxcyte to settle taxes on vested restricted stock, roughly 1.6% of the 164,000 shares he holds directly and through a family entity. More importantly, he carries the president and CFO titles at a company with no revenue, which makes the financing question his to answer.
On that front, Vaxcyte held $2.51 billion in cash and investments at the end of June, up slightly from $2.44 billion at the end of last year, and Guggenhime said in the August 5 release that the balance sheet leaves the company "well positioned to execute" on clinical, manufacturing and commercial-readiness milestones, as spending climbs to meet those milestones. Operating expenses reached $302.8 million in the second quarter against $226.2 million a year earlier, and the six-month net loss came to $604.9 million.
Some of that spending funds manufacturing for a commercial launch that requires trial data Vaxcyte doesn't have yet, but good results potentially coming in the fourth quarter make the buildout look prescient. Anything short of that leaves the company having pre-paid for a product it can't yet sell, with more readouts to get through before it can even file.
Should you buy stock in Vaxcyte right now?
Before you buy stock in Vaxcyte, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vaxcyte wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing

Key Points
The transactions represented a combined value of about $378,000 based on weighted average prices of $61.12 per share.
Jim Wassil traded shares equal to 4% of the stake held before the filing.
The disposition involved 2,705 shares withheld for tax obligations and the exercise and sale of 2,250 options under a Rule 10b5-1 trading plan.
Jim Wassil, Chief Operating Officer of Vaxcyte, Inc. (NASDAQ:PCVX), reported the sale of 6,182 shares of common stock on August 31 and September 1, totaling $378,000, according to an SEC Form 4 filing.
Transaction summary
Transaction value
~$378,000
Shares sold (directly held)
6,182
Post-transaction shares (directly held)
153,609
Post-transaction value
~$9.46 million
Transaction value based on SEC Form 4 weighted average sale price ($61.12); post-transaction value based on the September 2 market close ($61.58).
Key questions
What was the impact of the derivative transactions?
Wassil exercised 2,250 options at an exercise price of $5.35 per share, representing a significant discount to the weighted average execution price of $61.12. These shares were sold immediately as part of the total disposition.
How much of the trading volume was non-discretionary?
A portion of the activity involved 2,705 shares surrendered to the company to cover tax withholding obligations realized upon the vesting of restricted stock units. The remaining open-market sales were executed under a Rule 10b5-1 trading plan adopted on December 9, 2025.
What is the current status of the insider's equity position?
Following these transactions, Jim Wassil maintains direct ownership of 153,609 shares of common stock, which represents a 0.11% ownership interest in the company. The insider also holds 66,648 derivative securities.
How does the current stock price compare to the transaction level?
Shares of Vaxcyte were priced at $60.81 as of the September 1 market close, which is 0.51% below the weighted average price of $61.12 achieved during the reported transactions.
Company Overview
Share Price (as of market close 2026-09-01)
$60.81
Market Capitalization
$9.0 billion
Net Income (TTM)
-$1.1 billion
Company Snapshot
Vaxcyte is a clinical-stage biotechnology company focused on developing innovative protein-based vaccines to prevent and manage bacterial infectious diseases, with its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials.
The company operates a development-stage business model centered on advancing proprietary vaccine candidates through clinical trials with the objective of eventual commercialization and licensing partnerships with established pharmaceutical entities.
Vaxcyte's primary target markets include healthcare systems, public health agencies, and pharmaceutical partners seeking next-generation vaccines to address unmet medical needs in infectious disease prevention, particularly in immunocompromised and elderly populations.
Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees, focused on developing next-generation protein-based vaccines addressing significant gaps in infectious disease prevention. The company's strategic approach leverages advanced conjugate vaccine technology to create multi-valent formulations with enhanced immunogenicity and broader pathogen coverage compared to existing therapeutic options. With a market capitalization of $9.0 billion and a one-year share price appreciation of 95%, Vaxcyte represents investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector.
What this transaction means for investors
Wassil exercised 2,250 options struck at $5.35 and sold the shares along with the rest as part of a grant that predates most of what Vaxcyte has become. He scheduled the open-market portion under a plan adopted December 9, 2025, and had 2,705 shares withheld for taxes on vesting stock, leaving 153,609 shares plus 66,648 exercisable options.
Wassil runs operations, which at Vaxcyte means building the manufacturing base for a vaccine that isn't yet approved. Research and development spending hit $267.9 million in the second quarter against $194.2 million a year earlier, and the company attributed the increase partly to manufacturing activities supporting potential future commercial launches. Vaxcyte also needs a lot-to-lot consistency study, the trial proving it can make the same vaccine batch after batch, as the last Phase 3 piece before it can file with the FDA. Vaxcyte must wait to file for approval once that study finishes and the OPUS-2 and OPUS-3 results come in during the first half of 2027.
Should you buy stock in Vaxcyte right now?
Before you buy stock in Vaxcyte, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vaxcyte wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know

Key Points
The disposition of 6,289 shares at $61.20 per share represented a transaction value of about $384,900.
The transaction involved shares equal to 0.87% of the total equity stake held before the filing, resulting in a minor reduction of the overall position.
The shares were withheld by the issuer to satisfy tax obligations related to the vesting of restricted stock units.
Grant Pickering, the chief executive officer of Vaxcyte, Inc. (NASDAQ:PCVX), disposed of 6,289 shares of common stock in a non-discretionary transaction, according to an SEC Form 4 filing.
Transaction summary
Shares sold
6,289
Transaction value
~$384,900
Post-transaction shares (directly held)
~447,000
Post-transaction shares (indirectly held)
~266,400
Post-transaction value
$43.93 million
Transaction value based on SEC Form 4 weighted average sale price ($61.20); post-transaction value based on the September 2 market close ($61.58).
Key questions
Was the disposal a discretionary market sale?
The transaction was non-discretionary, as the shares were surrendered to the issuer solely to cover tax withholding obligations realized upon the vesting of restricted stock units.
How has the stock performed leading up to this filing?
Vaxcyte common stock has delivered a 95% total return over the 12-month period ending on the August 31 transaction date.
What is the breakdown of the CEO's indirect equity holdings?
Pickering's indirect position of 266,430 shares is divided equally between two separate trusts, with 133,215 shares held for his son and 133,215 shares held for his daughter.
What is the status of Vaxcyte's clinical pipeline?
The biotechnology company is currently focused on the clinical development of VAX-24, an experimental 24-valent pneumococcal conjugate vaccine in trials designed to address invasive pneumococcal disease and pneumonia.
Company Overview
Share Price (as of market close 2026-09-01)
$60.81
Market Capitalization
$9.0 billion
Net Income (TTM)
-$1.1 billion
Company Snapshot
Vaxcyte is a clinical-stage biotechnology company focused on developing innovative protein-based vaccines to prevent and manage bacterial infectious diseases, with its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine currently in clinical trials.
The company operates a development-stage business model centered on advancing proprietary vaccine candidates through clinical trials with the objective of eventual commercialization and licensing partnerships with established pharmaceutical entities.
Vaxcyte's primary target markets include healthcare systems, public health agencies, and pharmaceutical partners seeking next-generation vaccines to address unmet medical needs in infectious disease prevention, particularly in immunocompromised and elderly populations.
Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees, focused on developing next-generation protein-based vaccines addressing significant gaps in infectious disease prevention. The company's strategic approach leverages advanced conjugate vaccine technology to create multivalent formulations with enhanced immunogenicity and broader pathogen coverage than existing therapeutic options. With a market capitalization of $9.0 billion and a one-year share price appreciation of 95.12%, Vaxcyte represents investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector.
What this transaction means for investors
Pickering surrendered 6,289 shares to Vaxcyte for taxes when restricted stock vested, a rounding error against the 266,430 shares sitting in trusts for his two children. More importantly, he co-founded the company and runs it, and what he's running now relies on data set for release in the near future.
Vaxcyte expects topline data in the fourth quarter from OPUS-1, the pivotal Phase 3 trial testing VAX-31, its 31-strain pneumococcal vaccine, head to head against Pfizer's Prevnar 20 and Merck's Capvaxive in about 4,000 adults aged 50 and up. Two supporting trials read out in the first half of 2027, and only then does a filing for approval follow. The company remains "on track" for that release, Pickering said in an August 5 release.
Meanwhile, Vaxcyte burned $284.3 million in the June quarter alone, with R&D up 38% year over year to $267.9 million as manufacturing scales for a launch that hasn't been approved. The $2.5 billion in cash buys time, but a miss in OPUS-1 spends it on a vaccine that never sells. Right now, the company certainly has momentum so investors should stay focused on whether trial data helps that hold up.
Should you buy stock in Vaxcyte right now?
Before you buy stock in Vaxcyte, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vaxcyte wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm

(RTTNews) - Vaxcyte, Inc. (PCVX), a clinical-stage vaccine innovation company, announced the appointments of Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer. In addition, the company said that topline safety, tolerability and immunogenicity data from the Phase 3 OPUS-1 trial of VAX-31 are now expected by the end of October, ahead of previous guidance for a fourth-quarter 2026 readout.
The pivotal Phase 3 OPUS-1 trial is a randomized, double-blind, active-controlled clinical trial evaluating VAX-31 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults. The study is being conducted at approximately 50 sites in the United States.
Luis Jodar has more than 30 years of experience in vaccine development and launch across industry and health organisations. He spent 17 years at Pfizer Inc. and most recently served as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases.
David McAvoy brings more than three decades of legal leadership experience in the biopharmaceutical industry to Vaxcyte. He joins the company from Teva Pharmaceutical Industries Ltd., where he served as Executive Vice President and Chief Legal Officer.
"Luis and David join Vaxcyte at a pivotal time for the company," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
PCVX has traded between $30.81 and $65.00 over the last year. The stock closed Thursday's trade at $61.17, down 0.67%.
In the after-hours market, PCVX is down 1.24% at $60.41.
For more such biotechstock news visit www.rttnews.com.

Vaxcyte Appoints Luis Jodar, David McAvoy To Leadership Team; Accelerates Phase 3 VAX-31 Timeline

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 124,149 contracts has been traded thus far today, a contract volume which is representative of approximately 12.4 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 151.6% of UNH's average daily trading volume over the past month, of 8.2 million shares. Especially high volume was seen for the $400 strike call option expiring May 15, 2026, with 10,664 contracts trading so far today, representing approximately 1.1 million underlying shares of UNH. Below is a chart showing UNH's trailing twelve month trading history, with the $400 strike highlighted in orange:
MongoDB Inc (Symbol: MDB) options are showing a volume of 21,608 contracts thus far today. That number of contracts represents approximately 2.2 million underlying shares, working out to a sizeable 139.5% of MDB's average daily trading volume over the past month, of 1.5 million shares. Especially high volume was seen for the $177.50 strike put option expiring May 22, 2026, with 1,830 contracts trading so far today, representing approximately 183,000 underlying shares of MDB. Below is a chart showing MDB's trailing twelve month trading history, with the $177.50 strike highlighted in orange:
And Vaxcyte Inc (Symbol: PCVX) saw options trading volume of 19,518 contracts, representing approximately 2.0 million underlying shares or approximately 136.2% of PCVX's average daily trading volume over the past month, of 1.4 million shares. Particularly high volume was seen for the $50 strike put option expiring October 16, 2026, with 5,446 contracts trading so far today, representing approximately 544,600 underlying shares of PCVX. Below is a chart showing PCVX's trailing twelve month trading history, with the $50 strike highlighted in orange:
For the various different available expirations for UNH options, MDB options, or PCVX options, visit StockOptionsChannel.com.
Also see:
Steven Cohen Stock Picks
ZIPR Videos
YTD Return on Dow
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Tuesday Option Activity: UNH, MDB, PCVX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Vaxcyte Inc (Symbol: PCVX), where a total volume of 10,776 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 76.3% of PCVX's average daily trading volume over the past month, of 1.4 million shares. Especially high volume was seen for the $45 strike put option expiring October 16, 2026, with 3,067 contracts trading so far today, representing approximately 306,700 underlying shares of PCVX. Below is a chart showing PCVX's trailing twelve month trading history, with the $45 strike highlighted in orange:
Marvell Technology Inc (Symbol: MRVL) saw options trading volume of 160,810 contracts, representing approximately 16.1 million underlying shares or approximately 72% of MRVL's average daily trading volume over the past month, of 22.3 million shares. Particularly high volume was seen for the $100 strike call option expiring March 27, 2026, with 34,867 contracts trading so far today, representing approximately 3.5 million underlying shares of MRVL. Below is a chart showing MRVL's trailing twelve month trading history, with the $100 strike highlighted in orange:
And Corcept Therapeutics Inc (Symbol: CORT) options are showing a volume of 10,145 contracts thus far today. That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 71.8% of CORT's average daily trading volume over the past month, of 1.4 million shares. Especially high volume was seen for the $50 strike call option expiring April 17, 2026, with 2,322 contracts trading so far today, representing approximately 232,200 underlying shares of CORT. Below is a chart showing CORT's trailing twelve month trading history, with the $50 strike highlighted in orange:
For the various different available expirations for PCVX options, MRVL options, or CORT options, visit StockOptionsChannel.com.
Also see:
Chase Coleman Stock Picks
CVGW market cap history
Semiconductors Dividend Stocks
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Wednesday Option Activity: PCVX, MRVL, CORT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Crane Co (Symbol: CR), where a total of 3,621 contracts have traded so far, representing approximately 362,100 underlying shares. That amounts to about 96.2% of CR's average daily trading volume over the past month of 376,265 shares. Particularly high volume was seen for the $180 strike put option expiring April 17, 2026, with 1,500 contracts trading so far today, representing approximately 150,000 underlying shares of CR. Below is a chart showing CR's trailing twelve month trading history, with the $180 strike highlighted in orange:
Vaxcyte Inc (Symbol: PCVX) options are showing a volume of 11,180 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 88.9% of PCVX's average daily trading volume over the past month, of 1.3 million shares. Particularly high volume was seen for the $45 strike put option expiring October 16, 2026, with 3,750 contracts trading so far today, representing approximately 375,000 underlying shares of PCVX. Below is a chart showing PCVX's trailing twelve month trading history, with the $45 strike highlighted in orange:
And Piper Sandler Companies (Symbol: PIPR) options are showing a volume of 1,647 contracts thus far today. That number of contracts represents approximately 164,700 underlying shares, working out to a sizeable 81% of PIPR's average daily trading volume over the past month, of 203,395 shares. Particularly high volume was seen for the $265 strike call option expiring September 18, 2026, with 820 contracts trading so far today, representing approximately 82,000 underlying shares of PIPR. Below is a chart showing PIPR's trailing twelve month trading history, with the $265 strike highlighted in orange:
For the various different available expirations for CR options, PCVX options, or PIPR options, visit StockOptionsChannel.com.
Also see:
Barry Rosenstein Stock Picks
Funds Holding VEEV
Consumer Stocks Hedge Funds Are Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Monday Option Activity: CR, PCVX, PIPR

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $244.9 million dollar outflow -- that's a 3.0% decrease week over week (from 65,450,000 to 63,475,000). Among the largest underlying components of XBI, in trading today Moderna Inc (Symbol: MRNA) is up about 2.3%, Vaxcyte Inc (Symbol: PCVX) is up about 1%, and Roivant Sciences Ltd (Symbol: ROIV) is up by about 0.9%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $66.66 per share, with $132.09 as the 52 week high point — that compares with a last trade of $123.77. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
STG Average Annual Return
PHT Insider Buying
Top Ten Hedge Funds Holding PBCT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

XBI, MRNA, PCVX, ROIV: ETF Outflow Alert

(RTTNews) - Vaxcyte, Inc. (PCVX), a clinical-stage vaccine innovation company, reported its fourth-quarter and full-year 2025 financial results and provided a business update.
The company's lead program is VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate currently in a Phase 3 adult clinical program and a Phase 2 infant study. VAX-31 is designed to provide the broadest serotype coverage of any PCV in clinical development, aiming to prevent invasive pneumococcal disease (IPD) and pneumonia. The FDA has granted Breakthrough Therapy Designation for VAX-31 in adults.
In adults, three pivotal Phase 3 trials (OPUS-1, OPUS-2, and OPUS-3) are underway, enrolling thousands of participants to evaluate safety, tolerability, and immunogenicity compared to current standards of care, Prevnar 20 and Capvaxine. Topline data from OPUS-1 is expected in the fourth quarter of 2026, while readouts from OPUS-2 and OPUS-3 are anticipated in the first half of 2027.
In infants, enrolment has been completed in a Phase 2 dose-finding study, with topline data expected in the first half of 2027.
Beyond VAX-31, Vaxcyte is advancing:
•VAX-24, a 24-valent PCV candidate for infants, currently in Phase 2 clinical development, designed to cover more serotypes than any marketed infant PCV.
•VAX-XL, a third-generation PCV in early development, leveraging carrier-sparing conjugation technology to further expand coverage.
•VAX-A1, a novel vaccine candidate for Group A Strep, with a Phase 1 adult study planned for 2026.
•VAX-GI, a preclinical vaccine candidate targeting Shigella infections.
The company ended December 31, 2025, with cash, cash equivalents and investments of $2.4 billion.
For Q4 2025, net loss was $246.5 million, compared to $137.1 million in the year ago quarter. For the full year net loss widened to $766.6 million compared to $463.9 million from the prior year.
In Q4 2025, Vaxcyte incurred an additional $21.8 million in capital and facility buildout expenditures related to the construction of its dedicated Lonza manufacturing facility. By year-end, total expenditures reached $335.4 million, with the buildout completed in Q1 2026 within the original projected budget of up to $350 million. This facility is intended to support the potential global commercialization of the company's PCV program.
PCVX has traded between $27.66 and $83.33 over the past year. The stock closed Tuesday's session at $61.35, up 1.81%. In overnight trading Wednesday, the stock is down 2.97% at $59.53.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Vaxcyte Advances Adult 31-Valent Pneumococcal Phase 3 Trials, Completes Infant Phase 2 Enrollment

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $859.9 million dollar inflow -- that's a 11.1% increase week over week in outstanding units (from 62,850,000 to 69,850,000). Among the largest underlying components of XBI, in trading today Roivant Sciences Ltd (Symbol: ROIV) is up about 1.6%, Halozyme Therapeutics Inc (Symbol: HALO) is up about 1%, and Vaxcyte Inc (Symbol: PCVX) is lower by about 1.6%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $66.66 per share, with $132.09 as the 52 week high point — that compares with a last trade of $122.99. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Preferred Stock Ex-Dividend Calendar
Funds Holding TDY
DVYL Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Vaxcyte, Inc.

Options Strategies